Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Cervical Cancer Metastatic 2Recurrence 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 24Nivolumab 15Magnetic Resonance Spectroscopy 7Ipilimumab 6avelumab 5atezolizumab 5Specimen Handling 5Docetaxel 4lenvatinib 3durvalumab 3Paclitaxel 3Cyclophosphamide 3Carboplatin 3fludarabine 2cabozantinib 2aldesleukin 2Interleukin-2 2Fluorodeoxyglucose F18 2FAPI-46 2zanidatamab 1veliparib 1tislelizumab 1spartalizumab 1soluble LAG-3 protein, human 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × famitinib × Gynecologic × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡